Crossmark

Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study

Crossref DOI link: https://doi.org/10.1007/s10549-024-07458-9

Published Online: 2024-08-22

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Willis, Connor

Tan, Chia Jie

Chhibber, Anindit

Watanabe, Alexandre H.

Lam, Clara

Mehta, Sandhya

Kwong, Jackie

Park, Leah

Pavilack-Kirker, Melissa

Xu, Xiaoqing

Kelley, Kristen

Stenehjem, David https://orcid.org/0000-0002-1831-285X
Funding

Funding for this research was provided by:

AstraZeneca United States
License Information

Text and Data Mining valid from 2024-08-22

Version of Record valid from 2024-08-22
More Information

Article History

Received: 9 May 2024

Accepted: 7 August 2024

First Online: 22 August 2024

Declarations

:

: C.W., C.J.T., A.C., A.W., and D.S. received research funding through the University of Utah from AstraZeneca to conduct this study. C.L, L.P., M.P.K. and X.X. were employees of AstraZeneca while S.M. and J.K. were employees of Daiichi Sankyo at the time of the study.

: This study was exempted from ethical review by the University of Utah Institutional Review Board on 20 August 2020 (IRB_00134235).

Document is current

Any future updates will be listed below